A stroke organoids-multiomics platform to study injury mechanism and drug response
Source Zhu et al., 2025 · Stem Cell and Regenerative Medicine Lab, Institute of Clinical Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Translational Medicine Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College · 10.1016/j.bioactmat.2024.09.038
Abstract
This protocol establishes human iPSC-derived brain organoids exposed to hypoxic conditions to model ischemic stroke in vitro. The organoids are analyzed using proteomics, single-cell transcriptomics, and histopathology to identify pathological changes and test the therapeutic efficacy of traditional Chinese medicine (DengZhanShengMai capsule) on stroke-induced injury.
Protocol overview
22 steps across 6 phases
- 1 Dissociate hiPSC colonies into single cells
- 2 Feed embryoid bodies with fresh medium
- 1 Replace medium without Y27632
- 2 Transfer EBs to neural induction media
- 3 Feed EBs with additional neural induction medium
- 1 Embed EBs in Matrigel and initiate organoid differentiation
- 2 Feed organoids and continue static culture
- 3 Switch to media with vitamin A and begin orbital shaking
- 4 Maintain organoid culture with regular media changes
- 1 Prepare organoids for hypoxia treatment
- 2 Incubate organoids under hypoxic conditions
- 1 Fix organoids and brain tissue
- 2 Dehydrate mouse brain tissue
- 3 Dehydrate cerebral organoid tissue
- 4 Embed tissue in paraffin and section
- 5 Perform H&E staining
- 6 Perform immunofluorescence staining
- 1 Collect organoids for single-cell analysis
- 2 Dissociate organoids into single-cell suspension
- 3 Filter and wash cells
- 4 Count cells and assess viability
- 5 Perform single-cell 3′ RNA-seq
Full SOP
Create a free account to access this protocol
Join OrganMatch to unlock step-by-step procedures, reagent concentrations, QC checklists, and downloadable batch record templates.
Create free accountAlready registered? Log in
Attribution
This SOP was authored by Organthis based on the published method in Zhu et al., 2025. The originating laboratory holds no rights in this SOP and has not endorsed it unless marked Verified.
This wording is awaiting legal review.
Something wrong with this entry? Report an issue with this protocol